DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) announced new AI-enabled features ...
Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...
SAN FRANCISCO, April 15, 2025 /PRNewswire/ -- Stelo, a leading provider of enterprise-class data replication solutions, announced that it has successfully achieved Google Cloud Ready - BigQuery ...
Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA. The new CGM is designed for patients with Type 2 diabetes who do ...
In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
Organizations can purchase Stelo directly in their Azure environment to support data mirroring, streaming, and ingestion without added infrastructure complexity. Unlike more complex or multi-step ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results